Meticulous Research®—a leading global market research company, published a research report titled, ‘Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2029.’
According to this latest publication from Meticulous Research®, the global plasma fractionation market is projected to reach $46.9 billion by 2029, at a CAGR of 7.1% from 2022 to 2029. Manufacturing plasma-derived therapeutics requires regulated industrial processes to ensure optimal safety, quality, and recovery. Plasma derivatives are considered important therapeutic resources, owing to which the demand for plasma derivatives is rising. The plasma fractionation market is driven by the increasing prevalence of chronic diseases across all age groups, the growing use of immunoglobulins in various therapeutic areas, and the expansion of plasma collection centers. Furthermore, the growing prevalence of blood and respiratory diseases is creating opportunities for market growth.
The plasma fractionation market is segmented by product [Immunoglobulins (IVIG, SCIG, and IMIG), Coagulation Factors, Albumin, Protease Inhibitors, and Other Products), Application (Immunology, Hematology, Neurology, Critical Care, Hematology-oncology, Rheumatology & Orthopedics, and Other Applications), End User (Hospitals & Clinics, Clinical Research Laboratories, & Academic Institutes) and geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Based on product type, in 2022, the immunoglobulin segment is expected to account for the largest share of the plasma fractionation market. The immunoglobulins segment is further divided into intravenous immunoglobins (IVIg), subcutaneous immunoglobulins (SCIg), and intramuscular immunoglobulins (IMIg). In 2022, the IVIg segment is estimated to emerge as the largest share-holding segment. The growth of this sub-segment is attributed to factors such as high commercial availability and off-label use of IVIg for various indications in developed countries.
Based on application, in 2022, the neurology segment is expected to account for the largest share of the plasma fractionation market. The large market share of this segment is attributed to the use of plasma exchange as an established therapeutic procedure for various neurologic conditions such as multiple sclerosis, Rasmussen encephalitis, paraneoplastic disorders of the central nervous system (CNS), and acute forms of CNS demyelinating diseases.
Based on end user, the plasma fractionation market is segmented into hospitals & clinics, clinical research laboratories, and academic & research institutes. In 2022, the hospitals & clinics segment is expected to account for the largest market share. The factor attributed to the growth of this segment is the high adoption rates of plasma-derived products by hospitals & clinics, as plasma products form a crucial part of hospital & clinic supplies used for emergency cases.
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Indonesia, Vietnam, Thailand, Malaysia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Columbia, Peru, and Rest of Latin America), and the Middle East & Africa (South Africa and Rest of Middle East & Africa). In 2022, North America is expected to dominate the global plasma fractionation market. Factors such as the presence of an established network of plasma collection centers and the high prevalence of respiratory & autoimmune diseases in North America are contributing to the large share of this regional market.
Download Free Sample Report @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117
The key players operating in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), Takeda Pharmaceutical Company Limited (Japan), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Limited (BPL) (U.K.), Intas Pharmaceuticals Ltd. (India), LFB Group (France), ADMA Biologics, Inc. (U.S.), SK Plasma (South Korea), and GC Biopharma Corp. (South Korea)
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Dental Practice Management Software Market Worth $ 3.11 Billion by 2029Read More